| ID | 1072 |
| Name of the vaccine | Quadracel |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 4 to 6 years |
| Description of the vaccine | Diphtheria, Tetanus Toxoids, Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (DTaP vaccine). |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2015 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | 100% of immunized children achieved serum diphtheria and tetanus antitoxin levels of at least 0.01 IU/mL.
99 and 100% achieved serum antitoxin levels of at least 0.1 IU/mL.
After booster dose, 100% achieved serum antitoxin levels of at least 0.1 IU/mL. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose (0.5 mL) vials. |
| Mechanism of action | Serum tetanus antitoxin level of greater than or equal to 0.1 IU/mL is protective. |
| Route of administration | Intramuscular |
| Indications | If Quadracel is administered to immunocompromised persons, the expected immune response may not be obtained. |
| Export | Distributed by - Sanofi Pasteur Inc., USA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | Could be used for diphtheria, pertussis and poliovirus. |
| Side effects of vaccine | Pain, increase in arm circumference, erythema, swelling, myalgia, malaise, and headache. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/91640/download |
| Other name | NA |
| Additional Links | https://products.sanofi.ca/en/quadracel.pdf
|